IE 11 is not supported. For an optimal experience visit our site on another browser.

Neptune Technologies & Bioressources Inc. Incentive Stock Options -- Amendment

/ Source: GlobeNewswire

LAVAL, Quebec, Feb. 28, 2011 (GLOBE NEWSWIRE) -- Following Neptune Technologies & Bioressources Inc.'s ("Neptune") (Nasdaq:NEPT) (TSX-V.NTB) press release as of the date hereof announcing its presentation at Roth OC Growth Stock Conference on March 15, 2011, Neptune wishes to amend information on incentive stock options granted to Neptune's employees, officers and directors, as follows:

As of February 28, 2011, the Board of Directors of Neptune has decided to grant a total of 1,190,000 (1,145,000 previously announced) Neptune incentive stock options to employees, officers and directors. Neptune incentive stock options have an exercice price of $2.50 and a 3 year maturity. Insiders have been granted a total of 625,000 (575,000 previously announced) Neptune incentive stock options.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological disease driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular conditions within the over-the-counter, medical food and prescription drug markets. Acasti is in the process of listing its common shares on the TSX Venture Exchange.

NeuroBioPharm is pursuing pharmaceutical neurological applications, and a clinical study for a medical food product with a multinational partner is already initiated. The development of a prescription drug candidate is currently in progress. Advanced clinical development and commercialization is planned to be carried out with multinational partners.

"Neither NASDAQ nor the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

CONTACT: Neptune Contact: Neptune Technologies & Bioressources Inc. Andre Godin, V.P. Administration and Finance +1 450.687.2262 CEOcast Contact: Dan Schustack +1 212-732-4300 Howard Group Contact: Bob Beaty (888) 221-0915